The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2026 | AURORA: assessing a microwave ablation system in lung cancer
Ricky Thakrar, MBBS, MRCP, PhD, University College London, London, UK, discusses the AURORA trial (NCT07291973), a trial utilizing a flexible microwave ablation probe delivered via the Ion robotic bronchoscopy platform to treat patients with early lung cancer or metastatic nodules in the lung. Microwave ablation generates a homogeneous zone of thermal ablation by polarizing water molecules, and its use with a robotic platform may reduce complications associated with percutaneous approaches, such as pneumothorax. This interview took place at the 2026 British Thoracic Oncology Group (BTOG) congress in Edinburgh, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is the Aurora study and it is an early phase study, a first-in-man study using a flexible microwave ablation probe that is delivered with the Ion robotic bronchoscopy platform. So this is, so microwave ablation has been historically used percutaneously to treat patients with early lung cancer or metastatic nodules in the lung, or patients with metastatic nodules in the lung...
So this is the Aurora study and it is an early phase study, a first-in-man study using a flexible microwave ablation probe that is delivered with the Ion robotic bronchoscopy platform. So this is, so microwave ablation has been historically used percutaneously to treat patients with early lung cancer or metastatic nodules in the lung, or patients with metastatic nodules in the lung. Microwave ablation causes frictional heating by polarizing water molecules, and that causes a homogeneous zone of thermal ablation to target nodules. Patients who have had this done percutaneously are at risk of complications such as pneumothorax but potentially using it with a robotic platform may allow for lesser complications. The Aurora study will be looking at patients with early lung cancers and patients with metastatic nodules and we’ll be using a flexible microwave ablation probe to treat those patients who are not suitable for surgery or radiotherapy or who have chosen not to have surgery or radiotherapy treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
